| Market Capitalization (Millions $) |
3 |
| Shares
Outstanding (Millions) |
5 |
| Employees |
202 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-6 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Matinas Biopharma Holdings Inc
Matinas Biopharma Holdings Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative lipid-based pharmaceuticals. The company was founded in 2011 and is headquartered in Bedminster, New Jersey. Matinas Biopharma Holdings Inc. is committed to improving patients' lives by developing products that target unmet medical needs in infectious and inflammatory diseases.
Matinas Biopharma Holdings Inc. is focused on developing its proprietary lipid nanocrystal (LNC) delivery technology, which enables the enhanced absorption and targeted delivery of a wide range of therapeutic agents. The LNC technology is designed to improve the bioavailability of poorly soluble drugs, reduce toxicity, and enhance therapeutic efficacy. It has the potential to significantly impact the treatment of infectious and inflammatory diseases, including HIV/AIDS, hepatitis C, and cryptococcal meningitis.
Matinas Biopharma Holdings Inc. has a broad pipeline of products in development. The lead product candidate is MAT9001, an omega-3 fatty acid-based cardiovascular drug. MAT9001 is a prescription-only, omega-3 free fatty acid drug that is designed to treat patients with high triglycerides, a risk factor for cardiovascular disease. The company is also developing MAT2203, a LNC-formulated amphotericin B drug for the treatment of invasive fungal infections, including aspergillosis and candidiasis. The drug is currently in Phase 2 clinical trials.
The company has a team of experienced leaders and scientists, with expertise in drug development, pharmaceutical manufacturing, clinical research, and regulatory affairs. Matinas Biopharma Holdings Inc. has partnerships and collaborations with leading academic institutions, pharmaceutical companies, and government agencies to accelerate the development of innovative therapeutics.
In summary, Matinas Biopharma Holdings Inc. is a rapidly evolving biopharmaceutical company that is committed to improving the delivery of therapeutic agents for patients suffering from infectious and inflammatory diseases. With a pipeline of products in development and a team of experienced leaders and scientists, the company is well-positioned to create new and innovative treatments that will impact the lives of patients in need.
Company Address: 1545 Route 206 South Bedminster 7921 NJ
Company Phone Number: 484-8805 Stock Exchange / Ticker: NYSEAMER MTNB
|
2.39%